<DOC>
	<DOCNO>NCT01551212</DOCNO>
	<brief_summary>This trial evaluate efficacy Everolimus combination tacrolimus versus standard immunosuppressive regimen concern kidney function liver transplant recipient .</brief_summary>
	<brief_title>Efficacy Everolimus Combination With Tacrolimus Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion criterion : Male female recipient fullsize liver allograft , age 18 65 year . Exclusion criterion : Patients thrombocytopenia ( platelet &lt; 50,000/mm³ ) , absolute neutrophil count &lt; 1,000/mm³ leucopenia ( leucocytes &lt; 2000/mm³ ) , anemia Hb &lt; 8g/dl time screen Patients uncontrolled hypercholesterolemia ( &gt; 350mg/dL ; &gt; 9mmol/L ) hypertriglyceridemia ( &gt; 750 mg/dL ; &gt; 8.5 mmol/L ) time screen History malignancy organ system within past 5 year whether evidence local recurrence metastasis , nonmetastatic basal squamous cell carcinoma skin HCC ( see next criterion ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>kidney function</keyword>
</DOC>